Ani Pharmaceuticals Inc. (ANIP)
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI (ANIP) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.33 per share, beating the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.63 per share a year ago.
Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?
ANIP gears up for Q4 earnings as Cortrophin Gel sales are expected to have surged, with rare disease momentum building despite generic competition pressures.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
ANIP Stock Rises 7% in a Week: Here's What You Should Know
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance
ANI Pharmaceuticals delivered robust 2025 results and issued bullish 2026 guidance, targeting $1.055–$1.115 billion in revenues, up 60% year-over-year. Purified Cortrophin Gel remains the primary growth engine, projected to reach $540–$575 million in 2026, supported by a 90-person commercial expansion and a pivotal Phase 4 trial. ANIP's valuation is compelling at 11.2x forward P/E, a 43% sector discount, with strong liquidity ($285 million cash) and no cash burn anticipated.
Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength?
ANI (ANIP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
